Saturday 17 October 2026
Export QNRX’s income statement to Excel — free account
Quoin Pharmaceuticals, Ltd. Sponsored ADR
QNRX Healthcare Biotechnology
In the quarter to June 2026, EPS grew 69.8% and free cash flow fell 510.3%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
3.90
0.13
−3.23%
Follow QNRX
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | 241,500.00 | 308,700.00 | 220,500.00 | 33,180.00 | 8,400.00 | 8,925.00 | 466.20 | 127.40 | 14.88 | 5.01 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | 562,800.00 | 1,417,500.00 | 1,417,500.00 | 402,150.00 | 144,690.00 | 186,480.00 | 12,337.50 | 1,184.40 | 216.30 | 41.80 | |||||
| People | |||||||||||||||
| People | Employees | 18 | 24 | 28 | 14 | 12 | 4 | 4 | 4 | 5 | 6 | ||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | |||||
| EBT | (4) | (8) | (5) | (5) | (2) | (21) | (9) | (9) | (9) | (16) | |||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | (4) | (8) | (5) | (5) | (2) | (21) | (9) | (9) | (9) | (16) | |||||
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | (0.87) | (1.45) | (0.83) | (48,271.06) | (3,659.81) | (28,437.95) | (1,637.02) | (337.06) | (66.78) | (14.80) | |||||
| Cash flow | (0.82) | (0.92) | (0.97) | (58,840.00) | (2,231.00) | (7,150.12) | (1,462.19) | (304.82) | (59.62) | (12.68) | |||||
| Capex | (0.07) | (0.01) | (0.03) | (340.00) | (361.67) | (781.25) | (43.10) | 0.00 | 0.00 | 0.00 | |||||
| Free cash flow | (0.89) | (0.93) | (1.00) | (59,180.00) | (2,592.67) | (7,931.37) | (1,505.29) | (304.82) | (59.62) | (12.68) | |||||
| Book value | 1.63 | 0.97 | 0.57 | 42,930.00 | (11,012.17) | 821.25 | 1,277.03 | 219.53 | 69.84 | 12.28 | |||||
| Shares, m | 5 | 6 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | (4) | (5) | (6) | (6) | (1) | (6) | (8) | (8) | (8) | (14) | ||||
| Capex | 0 | 0 | 0 | 0 | 0 | (1) | 0 | — | — | — | |||||
| Free cash flow | (4) | (5) | (6) | (6) | (2) | (6) | (9) | (8) | (8) | (14) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | 8 | 7 | 4 | 4 | (8) | 4 | 10 | 8 | 11 | 14 | ||||
| Total debt | 0 | — | — | 0 | 1 | — | — | — | — | — | |||||
| Net debt | (8) | (8) | (5) | (5) | 1 | (7) | (13) | (11) | (14) | (19) | |||||
| Shareholders’ equity | 7 | 5 | 4 | 4 | (7) | 1 | 7 | 6 | 9 | 13 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | (65.07) | (92.62) | (75.23) | (83.30) | (55.53) | (399.87) | (79.33) | (65.25) | (64.30) | (87.56) | ||||
| ROIC | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | (78.87) | (126.74) | (117.27) | (121.45) | 181.08 | 721.40 | (234.30) | (132.92) | (120.56) | (141.59) | |||||
Negative figures in brackets.
Charts ten years each
Quoin Pharmaceuticals, Ltd. Sponsored ADR vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| IMRN IMMURON | $8.3M | — (loss-making) | — | +757.00% (above 0%: growing) | +12.00% (above 0%: growing) | +42.55% (above 0%: growing) | 72.16% | 0.00% | Compare |
| ADIL Adial Pharmaceuticals, Inc. | $8.3M | — (loss-making) | — | — | n/m | −263.66% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| BOLT Bolt Biotherapeutics, Inc. | $8.2M | — (loss-making) | — (loss-making) | −99.72% (below 0%: shrinking) | n/m | +38.87% (above 0%: growing) | 100.00% | (167,480.00%) | Compare |
| SNTI Senti Biosciences, Inc. | $8.1M | — (loss-making) | — (loss-making) | −98.68% (below 0%: shrinking) | n/m | −7.48% (below 0%: shrinking) | 100.00% | (85,229.41%) | Compare |
| QNRX Quoin Pharmaceuticals, Ltd. Sponsored ADR | $8.1M | — (loss-making) | — | — | n/m | −510.28% (below 0%: shrinking) | 0.00% | 0.00% | |
| XTLB XTL Biopharmaceuticals Ltd. | $8.1M | — (loss-making) | — | −39.32% (below 0%: shrinking) | n/m | +46.78% (above 0%: growing) | 0.00% | 0.00% | Compare |
| KPTI Karyopharm Therapeutics Inc. | $8.0M | — (loss-making) | — (loss-making) | −11.86% (below 0%: shrinking) | n/m | −33.34% (below 0%: shrinking) | 96.75% | (67.38%) | Compare |
| CNSP CNS Pharmaceuticals, Inc. | $7.9M | — (loss-making) | — | — | n/m | +33.70% (above 0%: growing) | 0.00% | 0.00% | Compare |
| APRE Aprea Therapeutics, Inc. | $7.8M | — (loss-making) | — (loss-making) | −98.40% (below 0%: shrinking) | n/m | −5.22% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| Median of peers | $8.1M | — | — | −68.86% | — | +14.24% | 84.46% | 0.00% |
Quoin Pharmaceuticals, Ltd. Sponsored ADR (QNRX) key facts
- Quoin Pharmaceuticals, Ltd. Sponsored ADR (QNRX) is a Biotechnology company in the Healthcare sector, traded in the US as an ADR.
- As of October 16, 2026, QNRX traded at $3.90, a market capitalization of $8.1 million.
- Return on equity was −141.6% and debt-to-equity 0.00.
Quoin Pharmaceuticals, Ltd. Sponsored ADR (QNRX) Latest News
No news at this impact. Lower the threshold for more.